Juliana Palacio Varona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juliana Palacio Varona has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- María Andrea Estévez-Flórez
Universidad El Bosque
2 shared publications - Ana María Rojas Manjarres
Faculty of Medicine, Fundación Universitaria Ciencias de la Salud, Bogotá, Colombia
1 shared publication Angelica Prada
Department of Ophthalmology, Fundación Oftalmológica de Santander - FOSCAL, Floridablanca, Colombia
1 shared publication- Brian Pérez Riaño
Universidad El Bosque
1 shared publication - Christian Armando Laverde Cubides
Hospital Simón Bolívar
1 shared publication - Diana Valeria Rey-Rodríguez
Universidad El Bosque
1 shared publication
Latest Publications
- 28 January 2026
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (3) , 542-552
Global, regional and national patterns in ROP research up to the pre-COVID-19 era: A systematic bibliometric review between 1950 to 2020
Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, predominantly affecting preterm infants. Global disparities in neonatal care and research capacity influence the volume and visibility of scientific production devoted to ROP across regions. This systematic bibliometric review aimed to characterize global, regional, and national patterns of ROP research published between 1950 and 2020, including temporal trends, geographic distribution, thematic focus, and citation impact. A systematic search of PubMed, Scopus, Web of Science, and SciELO identified 4,932 eligible articles. Most publications originated from the Region of the Americas (Pan American Health Organization, PAHO; 44.2%), the European Region (EURO; 28.0%), and the Western Pacific Region (WPRO; 16.0%). High-income countries accounted for 73.4% of the total output, whereas lower-middle- and low-income countries were markedly underrepresented. The most frequent research themes were risk/protective factors (25.0%) and treatment and outcomes (23.5%), while studies addressing surveillance and public health policies were scarce (6.3%). Scientific output increased markedly after the 1980s, with particularly rapid growth in recent decades in the Western Pacific and South-East Asia Regions. Citation analysis revealed substantial regional inequalities, with publications from high-income regions accounting for the majority of global citations and higher per-article impact. Overall, ROP research remains highly concentrated in high-income settings, reflecting persistent global disparities in scientific production and visibility. Strengthening research capacity and output in underrepresented regions is essential to promote more equitable evidence generation and to support informed decision-making in global eye health.
- 28 January 2026
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (3) , 542-552
Global, regional and national patterns in ROP research up to the pre-COVID-19 era: A systematic bibliometric review between 1950 to 2020
Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, predominantly affecting preterm infants. Global disparities in neonatal care and research capacity influence the volume and visibility of scientific production devoted to ROP across regions. This systematic bibliometric review aimed to characterize global, regional, and national patterns of ROP research published between 1950 and 2020, including temporal trends, geographic distribution, thematic focus, and citation impact. A systematic search of PubMed, Scopus, Web of Science, and SciELO identified 4,932 eligible articles. Most publications originated from the Region of the Americas (Pan American Health Organization, PAHO; 44.2%), the European Region (EURO; 28.0%), and the Western Pacific Region (WPRO; 16.0%). High-income countries accounted for 73.4% of the total output, whereas lower-middle- and low-income countries were markedly underrepresented. The most frequent research themes were risk/protective factors (25.0%) and treatment and outcomes (23.5%), while studies addressing surveillance and public health policies were scarce (6.3%). Scientific output increased markedly after the 1980s, with particularly rapid growth in recent decades in the Western Pacific and South-East Asia Regions. Citation analysis revealed substantial regional inequalities, with publications from high-income regions accounting for the majority of global citations and higher per-article impact. Overall, ROP research remains highly concentrated in high-income settings, reflecting persistent global disparities in scientific production and visibility. Strengthening research capacity and output in underrepresented regions is essential to promote more equitable evidence generation and to support informed decision-making in global eye health.
- Open Access
- 2 July 2025
- Published by Universidad de La Salle in Ciencia y Tecnología para la Salud Visual y Ocular
- Vol. 23 (1) , e5642
Effectiveness of the use of anti-vegf in eyes with corneal neovascularization: A review of the literature
Purpose: To identify, through a scoping review of the literature, the evidence regarding the efficacy of vascular endothelial growth factor inhibitor treatment in corneal neovascularization. Materials and methods: A literature search was implemented in medical indexing databases: Medline (Pubmed), Web Of Science, Embase, and Scielo of articles in both English and Spanish, through the terms MesH and DeCs: "Corneal Neovascularization," "Cornea," "Ranibizumab", "Lucentis" and "Vascular Endothelial Growth Factor" in the last ten years (2013 - 2023). Results: 6,124 articles were initially found, which, after review and selection, resulted in a final sample of 37 articles, of which only 19 were clinical studies or case reports. The studies were conducted in both humans and animals. They reported results that included all types of vascular endothelial growth factor (anti-VEGF) inhibitors available on the market, applied in different routes of administration, and with some combinations of therapies. The causes of corneal neovascularization varied widely. Conclusion: No adverse events were reported in any study, and all studies documented a decrease in the percentage or area of corneal neovascularization (NV) regardless of etiology or route of administration, being more effective topically and at higher doses. The most effective drugs were bevacizumab and ranibizumab, but more evidence is needed with experimental clinical studies in humans.
- 2 July 2025
- Published by Universidad de La Salle in Ciencia y Tecnología para la Salud Visual y Ocular
- Vol. 23 (1) , e5642
Open AccessEffectiveness of the use of anti-vegf in eyes with corneal neovascularization: A review of the literature
Purpose: To identify, through a scoping review of the literature, the evidence regarding the efficacy of vascular endothelial growth factor inhibitor treatment in corneal neovascularization. Materials and methods: A literature search was implemented in medical indexing databases: Medline (Pubmed), Web Of Science, Embase, and Scielo of articles in both English and Spanish, through the terms MesH and DeCs: "Corneal Neovascularization," "Cornea," "Ranibizumab", "Lucentis" and "Vascular Endothelial Growth Factor" in the last ten years (2013 - 2023). Results: 6,124 articles were initially found, which, after review and selection, resulted in a final sample of 37 articles, of which only 19 were clinical studies or case reports. The studies were conducted in both humans and animals. They reported results that included all types of vascular endothelial growth factor (anti-VEGF) inhibitors available on the market, applied in different routes of administration, and with some combinations of therapies. The causes of corneal neovascularization varied widely. Conclusion: No adverse events were reported in any study, and all studies documented a decrease in the percentage or area of corneal neovascularization (NV) regardless of etiology or route of administration, being more effective topically and at higher doses. The most effective drugs were bevacizumab and ranibizumab, but more evidence is needed with experimental clinical studies in humans.
- Open Access
- 12 December 2023
- Published by Universidad de La Salle in Ciencia y Tecnología para la Salud Visual y Ocular
- Vol. 21, 2
Impacto de la pandemia por covid-19 en la decisión de los pacientes sometidos a cirugía refractiva en una institución privada en Bogotá, Colombia
En el 2020, durante la pandemia por covid-19, disminuyeron los procedimientos en los centros de cirugía refractiva, pero resurgieron para octubre de ese mismo año, ya que aumentaron un 4 % en comparación con el 2019. Existe una información limitada sobre el impacto de la pandemia en la realización de cirugías y la razón que obedece a dicho aumento. Objetivo: identificar el efecto de la pandemia por covid-19 en la cirugía refractiva mediante la delimitación de las principales motivaciones para la realización del procedimiento. Métodos: estudio descriptivo observacional de corte transversal, por medio de la respuesta de un cuestionario sobre aspectos sociodemográficos y motivación quirúrgica. Resultados: fueron encuestados 203 participantes entre 31 y 40 años (47,8 %, n = 97), 18 y 30 años (39,9 %, n = 81) y mayores de 40 años (12,3 %, n = 25). El 61,1 % (n = 124) fueron mujeres y solo 3 (1,5 %) residían fuera de Colombia. Participaron con mayor frecuencia personas de estrato 4 (45,5 %) y 5 (24,3 %). Las principales motivaciones fueron: considerar que era el mejor momento para la cirugía, el deseo de evitar el uso de corrección óptica como respuesta al aumento del uso de pantallas y, por último, uso del tapabocas. Conclusiones: se demostró que el uso de tapabocas durante la pandemia, y el efecto de empañar las gafas, no fue una de las motivaciones más importantes, como sí lo fue el teletrabajo, pues la flexibilidad del horario laboral facilitó la posibilidad de la realización de cirugía refractiva, dejando este motivo como una de las posibles razones por las cuales se incrementaron los procedimientos realizados durante el 2020.
- 12 December 2023
- Published by Universidad de La Salle in Ciencia y Tecnología para la Salud Visual y Ocular
- Vol. 21, 2
Open AccessImpacto de la pandemia por covid-19 en la decisión de los pacientes sometidos a cirugía refractiva en una institución privada en Bogotá, Colombia
En el 2020, durante la pandemia por covid-19, disminuyeron los procedimientos en los centros de cirugía refractiva, pero resurgieron para octubre de ese mismo año, ya que aumentaron un 4 % en comparación con el 2019. Existe una información limitada sobre el impacto de la pandemia en la realización de cirugías y la razón que obedece a dicho aumento. Objetivo: identificar el efecto de la pandemia por covid-19 en la cirugía refractiva mediante la delimitación de las principales motivaciones para la realización del procedimiento. Métodos: estudio descriptivo observacional de corte transversal, por medio de la respuesta de un cuestionario sobre aspectos sociodemográficos y motivación quirúrgica. Resultados: fueron encuestados 203 participantes entre 31 y 40 años (47,8 %, n = 97), 18 y 30 años (39,9 %, n = 81) y mayores de 40 años (12,3 %, n = 25). El 61,1 % (n = 124) fueron mujeres y solo 3 (1,5 %) residían fuera de Colombia. Participaron con mayor frecuencia personas de estrato 4 (45,5 %) y 5 (24,3 %). Las principales motivaciones fueron: considerar que era el mejor momento para la cirugía, el deseo de evitar el uso de corrección óptica como respuesta al aumento del uso de pantallas y, por último, uso del tapabocas. Conclusiones: se demostró que el uso de tapabocas durante la pandemia, y el efecto de empañar las gafas, no fue una de las motivaciones más importantes, como sí lo fue el teletrabajo, pues la flexibilidad del horario laboral facilitó la posibilidad de la realización de cirugía refractiva, dejando este motivo como una de las posibles razones por las cuales se incrementaron los procedimientos realizados durante el 2020.